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It is believed that a large percentage of unprotected sex acts with an HIV-infected partner never 
result in virus transmission that leads to systemic infection. However, repeated HIV exposure that 
does not result in persistent infection may still influence the immune system of the uninfected 
partner. For example, both HIV-specific T cells and neutralizing antibodies have been detected in 
vaginal secretions or the seminal fluid of HIV-negative individuals believed to have been repeatedly 
exposed to HIV via unprotected sex with HIV-infected partners. A recent study by researchers in the 
Vaccine and Infectious Disease Division and their collaborators detected IgA antibodies with HIV 
antigen specificity in vaginal secretions of HIV seronegative women who participated in a 
microbicide trial in Africa. Their results were published in PLoS ONE. 
The first part of the study compared several sampling methods for obtaining vaginal secretions to 
detect IgG and IgA antibodies. From a cohort of five HIV-seropositive and five HIV-uninfected 
women in Seattle, the researchers determined that there was no statistical difference in antibody 
titers obtained from the three sampling devices tested. They also revealed that the IgG antibodies 
from the HIV-positive women reacted broadly across eight HIV-1 envelope antigens, but the IgA 
antibodies were only specific for the gp41 subunit. 
Having validated the methods for sample collection and HIV-specificity determination in vaginal 
secretions, the researchers next looked at samples obtained from 57 HIV-seronegative women 
comprising the control arm of a microbicide efficacy trial in Southern Africa. Of the 57 women, nine 
were found to have HIV-specific IgA antibodies, but no HIV-specific IgG antibodies were detected in 
any of the women. Interestingly, the vaginal IgA antibodies were directed at HIV Env gp120/gp140 
and gp41 in six and three women, respectively, which contrasted to the IgA antibodies detected in 
the HIV-positive women in Seattle, which were only specific for gp41. 
This study confirmed previous observations of mucosal HIV-specific IgA antibodies in uninfected 
women with a higher risk of exposure to HIV. The fact that these samples came from participants of 
a microbicide trial, even if they were from the untreated control group, may have provoked study 
organizer Dr. Florian Hladik to contemplate several lines of inquiry for further investigation. 
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"An important question now is whether an efficacious microbicide, one that successfully inactivates 
HIV, would lead these disabled viruses to stimulate a mucosal immune response," said Dr. Hladik. 
"In such a scenario, we should find mucosal anti-HIV antibodies more frequently in women using the 
active product than in women using a placebo." 
"The next question would then be whether these responses contribute to protection, so that HIV 
infection would be prevented by a two punch mechanism: direct antiviral activity of the microbicide 
plus emerging protective immunity stimulated by contact with inactivated viruses." 
He admits that this hypothesis may sound far-fetched, but cites evidence from a recent study to 
support his case. It showed "that a new class of highly cross-neutralizing antibodies likely requires 
immune stimulation with entire native viral spikes rather than just parts (Huang, et al. 2014)." Dr. 
Hladik speculates that, "microbicide-inactivated natural whole virions could provide just that kind of 
stimulation." 
 
This PLOS One study is part of a PLOS journals collection highlighting recent advances in HIV 
mucosal immunology. 
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Image provided by Dr. Florian Hladik 
Cervical swab samples from HIV-uninfected women 
revealed specificity to various HIV-1 Env antigens. For 
the 57 microbicide trial participating women, black 
symbols signify negative responses and colored 
symbols signify positive responses, with colors 
indicating specific women. 
 
